CDC and FDA Expedite the Availability of Additional Doses of New RSV Immunization for Infants
by
OneAdmin
November 16, 2023
Today, CDC announced the release of more than 77,000 additional doses of Beyfortus™ (nirsevimab-alip (100 mg), a long-acting monoclonal antibody designed to protect infants against severe respiratory syncytial virus (RSV) disease.